{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:30:16Z","timestamp":1790206216022,"version":"4.1.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T00:00:00Z","timestamp":1570147200000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Merck and Gilead Sciences"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF)-containing antiretroviral therapy (ART) can improve renal function and bone mineral density in people with human immunodeficiency virus (PWH). The switch can also negatively influence cholesterol, but changes in body mass index (BMI) and atherosclerotic cardiovascular disease (ASCVD) risk are unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective observational study evaluated BMI and ASCVD risk score changes in virologically suppressed PWH who switched from TDF to TAF without switching other ART regimen components. Adults on TDF for \u22651 year with 2 consecutive HIV ribonucleic acid values &amp;lt;200 copies\/mL before a TAF switch were included. Body weight, BMI, cholesterol, and ASCVD risk score were collected for the year before and after the switch. Pre- and postswitch values were compared with the Wilcoxon signed-rank test. Changes in BMI and ASCVD scores were modeled using generalized estimating equations regression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>One hundred ten patients were included. In unadjusted analyses, there were significant increases in weight, BMI, total cholesterol, LDL, HDL, and ASCVD risk score in the year after switching from TDF to TAF (each P \u2264 .01). In regression models, switching from TDF to TAF was associated with a 0.45 kg\/m2 increase in BMI (95% confidence interval [CI], 0.14\u20130.76) and a 13% increase in ASCVD risk score (95% CI, 4%\u201323%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We observed significant BMI and ASCVD score increases in PWH 1 year after switching from TDF to TAF. The mechanism of changes is unclear and requires additional study.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofz414","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T05:06:35Z","timestamp":1570165595000},"source":"Crossref","is-referenced-by-count":73,"title":["Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide"],"prefix":"10.1093","volume":"6","author":[{"given":"Jason J","family":"Schafer","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin N","family":"Sassa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn R","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Shimada","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College, Division of Biostatistics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W","family":"Keith","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College, Division of Biostatistics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A","family":"DeSimone","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Medical College, Division of Infectious Diseases, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,4]]},"reference":[{"key":"2020081005080901500_CIT0001","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","volume":"16","author":"Mills","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2020081005080901500_CIT0002","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/QAI.0000000000000908","article-title":"Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study","volume":"71","author":"Pozniak","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020081005080901500_CIT0003","article-title":"Switching from ritonavir or cobicistat boosted atazanavir (ATV) plus emtricitabine (FTC)\/tenofovir disoproxil fumarate (TDF) to a tenofovir alafenamide (TAF)-based single tablet regimen (STR): week 48 data in virologically suppressed adults","author":"Rijnders"},{"key":"2020081005080901500_CIT0004","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study","volume":"67","author":"Sax","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020081005080901500_CIT0005","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAI.0000000000000618","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study","volume":"69","author":"Mills","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020081005080901500_CIT0006","first-page":"S1","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"129","author":"Grundy","year":"2014","journal-title":"Circulation"},{"key":"2020081005080901500_CIT0007","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s15010-018-1227-0","article-title":"A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017","volume":"47","author":"Gomez","year":"2019","journal-title":"Infection"},{"key":"2020081005080901500_CIT0008","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two difference prodrugs of tenofovir to treat HIV","volume":"381","author":"Ventner","year":"2019","journal-title":"N Engl J Med"},{"key":"2020081005080901500_CIT0009","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3851\/IMP2348","article-title":"HIV infection and obesity: where did all the wasting go?","volume":"17","author":"Tate","year":"2012","journal-title":"Antivir Ther"},{"key":"2020081005080901500_CIT0010","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1089\/aid.2012.0234","article-title":"Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons","volume":"29","author":"Lakey","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2020081005080901500_CIT0011","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1093\/cid\/civ192","article-title":"Weight change after antiretroviral therapy and mortality","volume":"60","author":"Yuh","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020081005080901500_CIT0012","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/QAD.0b013e32832913ee","article-title":"Weight gain at 3 months of antiretroviral therapy is strongly associated with survival: evidence from two developing countries","volume":"23","author":"Madec","year":"2009","journal-title":"AIDS"},{"key":"2020081005080901500_CIT0013","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/hiv.12294","article-title":"Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study","volume":"17","author":"Achhra","year":"2016","journal-title":"HIV Med"},{"key":"2020081005080901500_CIT0014","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/QAI.0000000000001071","article-title":"Weight gain and incident diabetes among HIV-infected veterans initiating antiretroviral therapy compared with uninfected individuals","volume":"73","author":"Herrin","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020081005080901500_CIT0015","first-page":"635","article-title":"Progression to overweight, obesity and associated factors after antiretroviral therapy initiation among Brazilian persons with HIV\/AIDS","volume":"25","author":"Maia Leite","year":"2010","journal-title":"Nutr Hosp"},{"key":"2020081005080901500_CIT0016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1089\/aid.2015.0147","article-title":"Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada","volume":"32","author":"Koethe","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2020081005080901500_CIT0017","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/QAI.0000000000001450","article-title":"Increased risk of myocardial infarction in HIV-infected individuals in North America compared with the general population","volume":"75","author":"Drozd","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020081005080901500_CIT0018","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/jamainternmed.2013.3728","article-title":"HIV infection and the risk of acute myocardial infarction","volume":"173","author":"Freiberg","year":"2013","journal-title":"JAMA Intern Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofz414\/30038353\/ofz414.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/10\/ofz414\/33599116\/ofz414.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/10\/ofz414\/33599116\/ofz414.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T09:11:16Z","timestamp":1597050676000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofz414\/5571854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":18,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofz414","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,10,1]]},"article-number":"ofz414"}}